Industry News-Good Doctor

Blog

——

2026.06.18

Reprinted: 2026 Chinese Expert Consensus on Multidisciplinary Diagnosis and Treatment of Malignant Pleural Effusion Associated with Ovarian Cancer (2026 Edition)

Malignant pleural effusion (MPE) refers to pleural fluid accumulation resulting from primary malignant tumors of the pleura or from metastases of malignancies originating elsewhere that have spread to the pleura.

2026.05.27

Reposted: [Commentary] International Cutting-Edge Advances and Clinical Practice in the Diagnosis and Treatment of Pseudomyxoma Peritonei

The academic study of peritoneal pseudomyxoma (PMP) has been long and tortuous; only over the past four decades has a conceptual framework aligned with the core principles of oncology gradually taken shape.

2026.05.27

Good Doctor·Hyperthermic Perfusion | Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Pseudomyxoma Peritonei (PMP)

PMP is a rare clinical syndrome primarily caused by the dissemination and implantation of mucinous tumor cells within the peritoneal cavity, leading to the accumulation of mucinous ascites.

2026.05.20

Reprinted: [Article] A Multicenter Real-World Study of 940 Cases of Peritoneal Pseudomyxoma Treated with Cytoreductive Surgery Combined with Hyperthermic Intraperitoneal Chemotherapy

Objective: Based on multicenter data, to evaluate the long-term survival, perioperative severe adverse events, and prognostic risk factors in patients with peritoneal pseudomyxoma (PMP) treated with cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC).

2026.04.20

Good Doctor·Hyperthermic Intrathoracic Chemotherapy | Multidisciplinary Treatment of Malignant Pleural Effusion: HITHOC Is Superior to Traditional Methods in Controlling Effusion

2026.04.10

Reprinted: In-Depth Report on the Cutting Edge of Clinical Research on Peritoneal Metastatic Tumors Worldwide, 2021–2026

Peritoneal metastatic cancer (PM) was once regarded as a “terminal stage of cancer,” but rapid advances in diagnostic and therapeutic technologies are now ushering in a transformative turning point in this field. This review provides an in-depth analysis of cutting-edge developments in the treatment of peritoneal metastatic cancer from 2021 to 2026, with a particular focus on the optimization and innovation of the core strategy of cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC). It demonstrates how multidisciplinary team (MDT) approaches are reshaping patient outcomes and how precision diagnostics and minimally invasive techniques are bringing new hope to this refractory malignancy.

2026.03.31

Good Doctor·Hyperthermic Perfusion | Literature Review and Analysis | (II) “Clinical Study on Continuous Constant-Temperature Circulating Hyperthermic Perfusion for the Treatment of Malignant Ascites”

Case selection: The observation group comprised 22 patients aged 39–65 years, including 8 cases of gastric cancer, 5 cases of colorectal cancer, 6 cases of ovarian cancer, and 3 other cases; the control group consisted of 23 patients aged 38–70 years, with 6 cases of gastric cancer, 9 cases of colorectal cancer, 5 cases of ovarian cancer, and 3 other cases.

2026.03.31

Good Doctor·Hyperthermic Perfusion | Commentary on Literature | (1) "Clinical Application of Isothermal Circulating Hyperthermic Perfusion Chemotherapy in the Prevention and Treatment of Cavity Metastatic Cancer"

Guidelines for hyperthermic intraperitoneal chemotherapy (HIPEC) were first published in Europe in 2008 by the European Society of Surgical Oncology (ESSO) and the European Society of Gynaecological Oncology (ESGO), and in the United States in 2014 by the American Society for Peritoneal Surface Malignancies (ASPSM). In China, the CACA guidelines for HIPEC were released in 2023. To date, no guidelines for hyperthermic intrathoracic chemotherapy (HITHOC) have been issued either domestically or internationally. The authors of this article and their team began clinically applying body-cavity hyperthermic perfusion machines to treat 290 patients as early as 2006, successfully completing a total of 1,075 HIPEC or HITHOC procedures. They can thus be regarded as pioneers and trailblazers in this field.

< 1 2 3 4 5 > proceed page

· GDHIPEC from China ,

· Caring for Patients Worldwide ·

Tel.: +86 29 82681864

Sales service hotline: +86 15002902555

E-mail: gd029@126.com

Address: Floor 1-2, Left Building No. 1, Huoju Road, East zone of Xi’an High- tech Development District, Xi’an, China

COOKIES

Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy

COOKIES

required

These cookies are necessary for basic functions such as payment. Standard cookies cannot be turned off and do not store any of your information.

analyze

These cookies collect information, such as how many people are using our site or which pages are popular, to help us improve the customer experience. Turning these cookies off will mean we can't collect information to improve your experience.

Feature

These cookies enable the website to provide enhanced functionality and personalization. They may be set by us or by third-party providers whose services we have added to our pages. If you do not allow these cookies, some or all of these services may not function properly.

advertise

These cookies help us understand what you are interested in so that we can show you relevant advertising on other websites. Turning these cookies off will mean we are unable to show you any personalized advertising.

Internet Drug Information Service Qualification Certificate (Shaanxi)-Non-Operating -2023-0143

Blog

COOKIES

COOKIES

Sorry，The current column has no content!